ESTRO 2025 - Abstract Book

S2412

Interdisciplinary – Other

ESTRO 2025

4233

Digital Poster Quality of Life Outcomes in Patients Undergoing Proton Therapy Re-Irradiation: Insights from EORTC QLQ C30 questionnaire Maria Giulia Vincini 1 , Luca Bergamaschi 1 , Samantha Dicuonzo 1 , Marianna Alessandra Gerardi 1 , Annamaria Ferrari 1 , Giulia Marvaso 1,2 , Federico Mastroleo 1 , Gaia Piperno 1 , Roberto Orecchia 3 , Daniela Alterio 1 , Barbara Alicja Jereczek-Fossa 1,2 1 Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 2 Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy. 3 Scientific Directorate, IEO, European Institute of Oncology IRCCS, Milan, Italy Purpose/Objective The quality of life (QoL) of patients who undergo a re-irradiation (reRT) is crucial, as these treatments often follow a history of intensive interventions that can significantly impact physical and emotional well-being. This study aims to report data of QoL of patients who underwent Proton Therapy (PT)-reRT at our institution Material/Methods All pts treated with PT-reRT from November 2023 to October 2024 were invited to fulfill different patient-reported outcome (PRO) questionnaires (Proton Registry NCT05860361). This study reports the results of the QoL of PT-reRT patients assessed through the validated EORTC QLQ-C30 questionnaire, which includes 30 questions covering 3 domains: (i) functional scales ; (ii) symptom scales; (iii) global health status (1 score). Patients were ask to fill the questionnaire at baseline, at the end of PT-reRT, and 3 months after the end of PT-reRT. Patients with available data for at least one timepoint were included. The scoring procedure followed the EORTC QLQ-C30 Scoring Manual. Median values and boxplots were used to visualize the results. Results A total of 62 patients had available baseline QoL data. Among them, 43 and 26 had available questionnaire data at the end of RT and at 3 months of follow-up, respectively. Figure 1 shows the score distribution for each functional scale and for the global health status. The higher the score, the more healthy the patient is. The median values for each scale are between 75% and 100%, indicating a good overall health status of the patients at all timepoints. A worsening trend is only evident in the case of emotional functioning, whereas for the other functional scales the score distribution was stable and at 3 months post PB-reRT is very similar to the distribution before the treatment. Figure 2 shows the score distribution for symptom scales. A higher score denotes the presence of the symptom. For both fatigue and insomnia, the score distributions were found to be stable across all the timepoints. The other symptom scales are not shown since the median value was 0 for all the considered timepoints, pointing that the vast majority of patients did not report any of these symptoms.